Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5647263 | 0.87 | KCNH2 (0.44) | KCNH2GRM2GRM5LTA4HPTGS2 | |
| SCHEMBL5653700 | 0.86 | KCNH2 (0.37) | KCNH2GRM5LTA4HPTGS2 | |
| SCHEMBL14599402 | 0.78 | KCNH2 (0.49) | KCNH2PGR | |
| Lersivirine SCHEMBL508446 | 0.78 | KCNH2 (0.49) | KCNH2PGR | |
| Lersivirine SCHEMBL508854 | 0.76 | PGR (0.40) | KCNH2PGRPTGS2 | |
| SCHEMBL509168 | 0.75 | KCNH2 (0.46) | KCNH2PGR | |
| Lersivirine SCHEMBL509058 | 0.74 | KCNH2 (0.45) | KCNH2PGR | |
| SCHEMBL508735 | 0.74 | KCNH2 (0.45) | KCNH2PGR | |
| SCHEMBL508393 | 0.73 | KCNH2 (0.44) | KCNH2PGR | |
| Lersivirine SCHEMBL508803 | 0.73 | KCNH2 (0.44) | KCNH2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230025-B2 | Pyrazole derivatives | PFIZER, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230025-B2 | Pyrazole derivatives | PFIZER, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20040110816-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110816-A1 | Pyrazole derivatives | REV1, POLR2E, SARS1 | KCNH2 2890/4885ATM 4212/4885PGR 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.